Synthesis and pharmacology of benzoxazines as highly selective antagonists at M4 muscarinic receptors

Journal of Medicinal Chemistry

Volumn 45, Issue 14, 2002, Pages 3094-3102

  Böhme, Thomas M ^a   Augelli Szafran, Corinne E ^a   Hallak, Hussein ^a   Pugsley, Thomas ^a   Serpa, Kevin ^a   Schwarz, Roy D ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 (3 METHOXYPHENYL) 2 PROPYNYLOXYIMINO] 1 AZABICYCLO[2.2.1]HEPTANE; 3 HYDROXYBENZYLHYDRAZINE; 3,6A,11,14 TETRAHYDRO 9 METHOXY 2 METHYL 12H ISOQUINO[1,2 B]PYRROLO[3,2 F][1,3]BENZOXAZINE 1 CARBOXYLIC ACID ETHYL ESTER; BENZOXAZINE DERIVATIVE; CATECHOLAMINE; LEVODOPA; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC M5 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; SNAKE VENOM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CATECHOLAMINE SYNTHESIS; CONTROLLED STUDY; CORPUS STRIATUM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; LIMBIC CORTEX; LOCOMOTION; MALE; NONHUMAN; RAT; RECEPTOR AFFINITY;

ANIMALS; ANTHRACENES; BICYCLO COMPOUNDS, HETEROCYCLIC; BINDING, COMPETITIVE; BIOLOGICAL AVAILABILITY; BLOOD-BRAIN BARRIER; CHO CELLS; CRICETINAE; DIHYDROXYPHENYLALANINE; HUMANS; MALE; MOTOR ACTIVITY; MUSCARINIC AGONISTS; MUSCARINIC ANTAGONISTS; OXAZINES; OXIMES; RATS; RATS, LONG-EVANS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTOR, MUSCARINIC M1; RECEPTOR, MUSCARINIC M4; RECEPTORS, MUSCARINIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037019266     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm011116o     Document Type: Article

References (32)

1. Rhodopsin photoreceptor of the rod cell: An emerging pattern for structure and function
2. Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes
3. Therapeutic opportunities for muscarinic receptors in the central nervous system
4. Mutational analysis of the relative orientation of transmembrane helices I and VII in G protein-coupled receptors
5. Selective muscarinic receptor agonists and antagonists
6. Differential response of striatal dopamine and muscarinic cholinergic receptor suptypes to the loss of dopamine. 3. Results in Parkinsons-disease cases
7. Anti-Parkinson medication and extrapyramidal reactions-study of trihexyphenidyl
8. Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes
9. PD 102807, a novel muscarinic M4 receptor antagonist, discriminates between striatal and cortical muscarinic receptors coupled to cyclic AMP
10. Muscarinic antagonists in substantia Nigra influence the decarboxylation of L-dopa in striatum
11. Identification and characterization of M4 selective muscarinic antagonists
12. Antagonist binding profiles of five cloned human muscarinic receptor subtypes
13. Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells
14. Design and synthesis of M1-selective muscarinic agonists: (R)-(-)-(Z)-1-azabicyclo-[2.2.1]heptan-3-one, O-(3-(3′-methoxyphenyl)-2-propynyl)oxime maleate (CI-1017), a functionally M1-selective muscarinic agonist
15. The synthesis of isoquinolines using methylthio activating groups
16. International union of pharmacology. XVIII. Classification of muscarinic acetylcholine receptors
17. Toxin from the green mamba dendroaspis angusticeps: Amino acid sequence and selectivity for the M4 receptors
18. Molecular basis of muscarinic acetylcholine receptor function
19. 1 receptors
20. Effects of oxotremorine and physostigmine on the turnover of dopamine in the corpus striatum and the limbic system
21. 2-muscarinic drugs on striatal dopamine release and metabolism in freely moving rats
22. Nicotinic and muscarinic components of rat brain dopamine synthesis stimulation induced by physostigmine
23. 2 muscarinic drugs on striatal dopamine release and metabolism: An in vivo microdialysis study comparing normal and 6-hydroxydopamine-lesioned rats
24. 1 muscarinic xanomeline (LY 246708/NNCII-0232)
25. On the presence in the cerebral cortex of muscarinic receptor subtypes which differ in neuronal localization, function and pharmacological properties
26. Expression of muscarinic acetylcholine and dopamine MRNAs in rat basal ganglia
27. Immunological localization of M1M5 muscarinic acetylcholine receptors in peripheral tissues and brain
28. Ueber das aethenylamidoxim und abkömmlinge desselben
29. Pharmacological estimation of drug-receptor dissociation constants. Statistical evaluation, II. Competitive antagonists
30. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (150) of an enzymatic reaction
31. Agonist antagonist interaction on dopamine receptors in brain, as reflected in rates of tyrosine and tryptophan hydroxylation
32. Effects of the dopamine D3 agonist PD 128907 on brain dopamine synthesis in rat